Andrew Schiermeier
Chief Executive Officer bij AvenCell Therapeutics, Inc.
Profiel
Andrew D. Schiermeier is lid van de raad van bestuur van Kynan Pharmaceuticals en Chief Operating Officer van Intellia Therapeutics, Inc. In zijn vorige carrière bekleedde hij de functie van Chief Operating Officer bij Aura Biosciences, Inc. en Senior CP & Head-Oncology Business bij Merck KGaA. Hij behaalde een MBA aan het College des Ingenieurs, een doctoraat aan Harvard University en een graduaat aan Stanford University.
Actieve functies van Andrew Schiermeier
| Bedrijven | Functie | Begin |
|---|---|---|
| Kynan Pharmaceuticals | Director/Board Member | - |
AvenCell Therapeutics, Inc.
 AvenCell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AvenCell Therapeutics, Inc. is a biopharmaceutical company that develops immunotherapies to treat cancers. The private company is based in Cambridge, MA and has subsidiaries in Germany. Andrew D. Schiermeier has been the CEO of the company since 2021. | Chief Executive Officer | 01-08-2021 |
Regel Therapeutics Inc.
 Regel Therapeutics Inc. BiotechnologyHealth Technology Regel Therapeutics Inc. develops a proprietary technology platform related to gene therapy. The company is based in Cambridge, MA. The company was founded in 2020 by Navneet Matharu, Jordane Dimidschstein, Steven B. Ruchefsky, Michael Jasulavic, Orrin Devinsky. Steven B. Ruchefsky has been the CEO since 2020. | Director/Board Member | - |
Eerdere bekende functies van Andrew Schiermeier
| Bedrijven | Functie | Einde |
|---|---|---|
| INTELLIA THERAPEUTICS, INC. | Chief Operating Officer | 21-06-2021 |
| MERCK KGAA | Corporate Officer/Principal | 01-01-2016 |
| AURA BIOSCIENCES, INC. | Chief Operating Officer | 01-05-2013 |
Opleiding van Andrew Schiermeier
| Harvard University | Doctorate Degree |
| Stanford University | Graduate Degree |
| College des Ingenieurs | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| MERCK KGAA | Health Technology |
| AURA BIOSCIENCES, INC. | Health Technology |
| INTELLIA THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
| Kynan Pharmaceuticals | |
AvenCell Therapeutics, Inc.
AvenCell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AvenCell Therapeutics, Inc. is a biopharmaceutical company that develops immunotherapies to treat cancers. The private company is based in Cambridge, MA and has subsidiaries in Germany. Andrew D. Schiermeier has been the CEO of the company since 2021. | Health Technology |
Regel Therapeutics Inc.
Regel Therapeutics Inc. BiotechnologyHealth Technology Regel Therapeutics Inc. develops a proprietary technology platform related to gene therapy. The company is based in Cambridge, MA. The company was founded in 2020 by Navneet Matharu, Jordane Dimidschstein, Steven B. Ruchefsky, Michael Jasulavic, Orrin Devinsky. Steven B. Ruchefsky has been the CEO since 2020. | Health Technology |
